XAIR 10-Q filed 2026-11-12 | Key takeaways
XAIR filed its 10-Q; the most relevant disclosure change is added Assets and liabilities held for sale: In August 2026, the company entered into a definitive agreement to sell its entire controlling stake in NeuroNOS Israel Ltd. to UNIVO Pharmaceutical Industries Ltd. for 19.99% of UNIVO's issued and outstanding share capital, five-year warrants to purchase addi. Customer concentration: Two third-party vendors represented 97% of other; First third-party vendor (largest) represented 79% of other.
Key takeaways
Net loss: Q2 FY2026 net loss attributable to Beyond Air was $7.8 million or $3.76 per share, compared to $7.9 million or $24.98 per share in Q2 FY2025; per-share loss improved significantly due to reverse stock split and increased share count.
NeuroNOS Israel disposal: In August 2026, the company agreed to sell its entire controlling stake in NeuroNOS Israel to UNIVO Pharmaceutical for 19.99% of UNIVO shares, five-year warrants, and up to $32.5 million in future milestone payments; transaction expected to close December 2026.
July 2026 private placement: The company raised $10.2 million gross ($9.1 million net) through issuance of 167,011 common shares, 1,638,835 pre-funded warrants, and 1.8 million each of Series A and Series B warrants.
Supplier concentration: In Q2 FY2026, approximately 97% of materials were purchased from two vendors (79% and 18%), up from 90% concentration in Q2 FY2025.
Nasdaq compliance: The company regained compliance with Nasdaq's $1.00 minimum bid price rule in August 2026 following the reverse stock split and is subject to a one-year Discretionary Panel Monitor.
Going concern: Management concluded the company will require additional funding within one year given cash used in operations of $10.5 million for the six months ended September 30, 2026 and accumulated deficit of $335.3 million.
Key metrics
Customer concentration
Disclosure changes
- Assets and liabilities held for sale
In August 2026, the company entered into a definitive agreement to sell its entire controlling stake in NeuroNOS Israel Ltd. to UNIVO Pharmaceutical Industries Ltd. for 19.99% of UNIVO's issued and outstanding share capital, five-year warrants to purchase additional UNIVO shares representing 19.99% of outstanding equity awards at $0.01 per share, and up to $32.5 million in future cash development and commercial milestone payments. Assets and liabilities of the NeuroNOS Israel disposal group were classified as he...
This represents a significant corporate action affecting the NeuroNOS segment and provides insight into the company's strategic restructuring and future milestone payment potential. - Private placement equity offering
In July 2026, the company raised approximately $10.2 million in gross proceeds through a private placement with institutional investors and company officers, issuing 167,011 shares of common stock, 1,638,835 pre-funded warrants, and 1,805,846 each of Series A and Series B warrants. Net proceeds after fees were approximately $9.1 million.
This equity raise provides needed capital to fund operations but results in significant dilution to existing shareholders. - Reverse stock split
The company effectuated a one-for-twenty (1:20) reverse stock split on July 13, 2026. Common stock began trading on a split-adjusted basis on July 13, 2026. As of September 30, 2026, there were 1,620,615 shares outstanding.
The reverse stock split was implemented to regain Nasdaq compliance with the minimum bid price requirement and impacts per-share metrics significantly. - Nasdaq compliance and monitoring
On April 7, 2026, the company received notice from Nasdaq of non-compliance with the $1.00 minimum bid price requirement. Following a hearing, the company was granted an exception subject to demonstrating compliance by July 31, 2026. The company regained compliance in August 2026 following the reverse stock split and is now subject to a one-year Discretionary Panel Monitor during which the company cannot submit a compliance plan to Nasdaq staff for any deficiency.
Delisting risk was materialized but resolved; ongoing monitoring period creates continued listing risk for any future non-compliance. - Warrant liability
Warrant liability was $0 as of September 30, 2026, compared to $2,000 as of March 31, 2026. The change in fair value of warrant liability was a $2,000 gain for the six months ended September 30, 2026.
Reduction to zero warrant liability reduces potential future dilution from liability-classified warrants. - Supplier concentration
In the three months ended September 30, 2026, the company purchased approximately 97% of its materials from two third-party vendors, with these vendors representing 79% and 18%, respectively. In the six months ended September 30, 2026, approximately 96% of materials were purchased from two vendors (84% and 12%).
Very high supplier concentration creates significant supply chain risk; one vendor now represents 79-84% of materials.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow XAIR in real time
Get material earnings, filing, IR, and earnings-call alerts by email.